Alzheon | Preserving future memories2018-02-06T17:21:00+00:00

A targeted approach to Alzheimer’s disease

Alzheon is developing ALZ-801, one of the few oral drug candidates in advanced stages of clinical testing in Alzheimer’s disease (AD). ALZ-801 has a favorable safety profile and the potential to slow the course of the disease in patients with Alzheimer’s.

ALZ-801, an improved prodrug formulation, builds upon a large dataset in AD patients treated with the active molecule, tramiprosate.  Using a targeted approach in our Phase 3 trial, we intend to enroll APOE4/4 homozygous patients with mild AD.

About ALZ-801

Press Releases